Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”

• Published in: Cancer treatment and research communications 2024, Vol.40, p.100806, Article 100806
• Main Author: Patra, Pritish Chandra
• Format: Article
• Language: English
• Subjects: ABVD; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; AVD; Bleomycin - administration & dosage; Bleomycin - therapeutic use; Brazil - epidemiology; Dacarbazine - therapeutic use; Doxorubicin - therapeutic use; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin's lymphoma; Humans; Retrospective Studies; Vinblastine - therapeutic use
• ISSN: 2468-2942; 2468-2942
• DOI: 10.1016/j.ctarc.2024.100806

•AVD as upfront treatment in newly diagnosed Hodgkin's Lymphoma resulted in overall response rate of 93 % and relapse rate of 13 % in Brazil.•The omission of bleomycin did not change the five-year overall survival of patients with classical Hodgkin's Lymphoma (p = 0.531) as compared to the arm with bleomycin (ABVD). The article “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study” have presented the experience of AVD chemotherapy regimen in newly diagnosed Hodgkin's lymphoma (HL) in a single center in Brazil. Though being a small retrospective study, results from this study have provided the medical community a real-world data on HL in Brazil. ABVD has remained the standard of care for patients of newly diagnosed HL both in early and advance stages. Newer targeted molecules have also come for use in novel combinations with existing drugs. However, in a situation of temporary scarcity of bleomycin due to lack of supply during 2017 in Brazil led to use of incomplete ABVD regimen without bleomycin, i.e. AVD for HL. However, Soldi et al. utilized the opportunity to retrospectively study if the omission of bleomycin leads to subnormal treatment or unwarranted effects.